References

Episode 1 – Clinical Advances of ARV – Professor Jürgen Rockstroh.

  1. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014 Jul 19;384(9939):241-8.
  2. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. 
  3. https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
  4. Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, Logeais M, Rimland D, Rodriguez-Barradas MC, Ruser C, Justice AC. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015 Jun 15;60(12):1852-9.
  5. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis. 2018 Jul 18;67(3):411-419.
  6. Hoffmann C, Schewe K, Fenske S, Buhk T, Sabranski M, Adam A, Hansen S, Stellbrink HJ. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice. Antivir Ther. 2020;25(2):83-90.
  7. Simões D, Stengaard AR, Combs L, Raben D; EuroTEST COVID-19 impact assessment consortium of partners. Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020. Euro Surveill. 2020 Nov;25(47):2001943
  8. Gilead Sciences Biktarvy product information.

Episode 2 – Innovations in Getting to Zero – Adjunct Professor Darren Russell

  1. Anderson PL et al. Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012 September 12; 4(151) doi:10.1126/scitranslmed.3004006.
  2. Molina JM et al. Efficacy, safety and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 2017. http://dx.doi.org/10.1016/S2352-3018(17)30089-9
  3. McCormack et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016 http://dx.doi.org/10.1016/S0140-6736(15)00056-2
  4. Bavinton BR et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet 2018 http://dx.doi.org/10.1016/S2352-3018(18)30132-2
  5. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. J Am Med Assoc 2016; 316: 171–81.
  6. National update on HIV, viral hepatitis and sexually transmissible infections in Australia: 2009–2019. Sydney: Kirby Institute, UNSW Sydney. Available from: https://data.kirby.unsw.edu.au/
  7. The Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) PrEP Guidelines Update. Prevent HIV by Prescribing PrEP. Sydney, 2019. Available from: https://prepguidelines.com.au/
  8. Gilead Sciences Biktarvy product information.

Episode 3 – Understanding ARV Safety – Dr Mina John

  1. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807
  2. El-Sadr WM et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med, 355 (22) (2006)
  3. Dalwadi DA, et al. Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs. Pharmacol Rev. 2018 Jul;70(3):684-711. doi: 10.1124/pr.117.013706. PMID: 29945900.
  4. Hoffman C and Llibre J. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21(1):4-10 doi: 10.24875/AIDSRev.19000023
  5. Molina JM et al. Switching to a fixed-dose bictegravir, emtricitabine and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV 2018 http://dx.doi.org/10.1016/S2352-3018(18)30092-4
  6. Silverberg MJ, et al. Changes in body mass index over time in persons with and without HIV. AIDS 2020. Oral OAB0603
  7. Venter WDF et al. Dolutegravir, emtricitabine plus two prodrugs of tenofovir to treat HIV. N Engl J Med. 2019. doi: 10.1056/NEJMoa1902824
  8. Gilead Sciences Biktarvy product information.

Episode 4 – Understanding ARV Resistance – Professor Don Smith

  1. Cohen CJ.  Successful HIV treatment: lessons learned. J Manag Care Pharm 2006;12(suppl S-b):S6–S11
  2. Kuritzkes DR. et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996;10:975-81
  3. Andreatta K et al. Integrase inhibitor resistance selections initiated with drug resistant HIV-1. CROI 2018. Abstract 546
  4. Aboud M, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019 Mar;19(3):253-264. doi: 10.1016/S1473-3099(19)30036-2. Epub 2019 Feb 4. PMID: 30732940.
  5. Nyaku AN, et al; ACTG A5353 Study Team. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564. PMID: 30668695; PMCID: PMC6477973.
  6. Acosta R et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) + F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. JAIDS 2020. DOI: 10.1097/QAI.0000000000002454.
  7. Gilead Sciences Biktarvy product information.

Episode 5 – Dr Vincent Cornelisse – Marginalised Communities and HIV

  1. UNAIDS. Prevailing against pandemics by putting people at the centre. World AIDS Day report 2020.  Available from: https://aidstargets2025.unaids.org/#section-targets
  2. Van Beek I. Case Study: Accessible primary healthcare- a foundation to improve health outcomes for people who inject drugs. Int J Drug Policy. 2007 Aug;18(4):329-32.doi:10.1016/j.drugpo.2006.11.005. Epub 2007 Jan 5
  3. Syme T, Jeanes M. Psychiatric disorders in people with HIV infection. 2019. HIV Management in Australasia. A guide for clinical care.
  4. Spearman W et al. Hepatitis C. Lancet 2019. DOI:https://doi.org/10.1016/S0140-6736(19)32320-7
  5. Grulich A et al. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. Lancet HIV. 2021. Jun 30;S2352-3018(21)00074-6. doi: 10.1016/S2352-3018(21)00074-6.
  6. Howarth AR et al.  The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London. HIV Medicine 2021. May 5. doi: 10.1111/hiv.13103. Online ahead of print
  7. The Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) PrEP Guidelines Update. Prevent HIV by Prescribing PrEP. Sydney, 2019. Available from: https://prepguidelines.com.au/
  8. Phillips TR et al. “Moving from one environment to another, it doesn’t automatically change everything”. Exploring the transnational experience of Asian-born gay and bisexual men who have sex with men newly arrived in Australia. PLoS One. 2020 Nov 20;15(11):e0242788. doi: 10.1371/journal.pone.0242788. eCollection 2020
  9. Ward J et al. HIV incidence in Indigenous and non-Indigenous populations in Australia: a population-level observational study. Lancet 2018. http://dx.doi.org/10.1016/S2352-3018(18)30135-8
  10. Acosta R et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) + F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. JAIDS 2020. DOI: 10.1097/QAI.0000000000002454
  11. Gilead Sciences Biktarvy product information.

Episode 6 – Dr Sorana Segal-Maurer – Thriving not Surviving

  1. www.unaids.org/en/resources/fact-sheet accessed Dec 2020
  2. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics
  3. National update on HIV, viral hepatitis and sexually transmissible infections in Australia: 2009–2019. Sydney: Kirby Institute, UNSW Sydney. Available from: https://data.kirby.unsw.edu.au/
  4.  https://www.cdc.gov/hiv/group/age/olderamericans/index.html
  5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ AdultandAdolescentGL.pdf. Accessed August 2021
  6. Wasserman P et al. High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite CD4 cell reconstitution and viral suppression. J Int Assoc Provid AIDS Care. 2014 Mar-Apr;13(2):145-52. doi: 10.1177/2325957413495919.
  7. Deeks SG et al. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2;382(9903):1525-33. doi: 10.1016/S0140-6736(13)61809-7. 
  8. Hsue P. Reducing Inflammation in HIV patients. IDWeek 2018. Abstract 905
  9. Wong C et al. Multimorbidity among persons living with HIV in the USA. Clin Infect Dis. 2018 Apr 3;66(8):1230-1238.doi: 10.1093/cid/cix998
  10. Living well with HIV. Lancet Editorial 2019. Published Online November 24, 2019 https://doi.org/10.1016/ S2352-3018(19)30379-0
  11. Safreed-Harmon K et al. Reorientating health systems to care for people with HIV beyond viral suppression. Lancet HIV. 2019 Dec;6(12):e869-e877.doi: 10.1016/S2352-3018(19)30334-0
  12. Kall M et al. Patient reported outcomes to enhance person-centred HIV care. Lancet HIV. 2020 Jan;7(1):e59-e68. doi: 10.1016/S2352-3018(19)30345-5
  13. Saag MS et al. Antiretroviral drugs for the treatment and prevention of HIV infection in adults 2020 recommendations of the International Antiviral Society – USA Panel. JAMA 2020. Available from: https://jamanetwork.com/journals/jama/fullarticle/2771873 
  14. Gilead Sciences Biktarvy product information.

Gilead Medical Information: 1800 806 112. Gilead, the Gilead logo and Creating Possible tagline are trademarks of Gilead Sciences, Inc. or one of its related companies. ©2021 Gilead Sciences, Inc. All rights reserved. Level 6, 417 St Kilda Road, Melbourne, VIC 3004. Date of Preparation: April 2021. AU-BVY-0060. This is a non-promotional medical education resource intended for healthcare professionals.